Table 3

Baseline characteristics of the enrolled patients in AdaPT-study – compared to other trials

VALUE [16]
 ASCOT-BPLA [17]
 DREAM [6,38]
 AdaPT

Valsartan
 Amlodipine
 Amlodipine
 Atenolol
 Ramipril
 Placebo
 ACEi
 Diuretic

(n = 7649)
 (n = 7596)
 (n = 9639)
 (n = 9618)
 (n = 2.623)
 (n = 2.646)
 (n = 1.353)
 (n = 662)
Age (mean, years)
 67.2 ± 8.2
 67.3 ± 8.1
 63.0 ± 8.5
 63.0 ± 8.5
 54.7 ± 10.9
 54.7 ± 10.9
 67.3 ± 10.4
 66.5 ± 10.2
Male gender (%)
 57.6
 57.5
 77
 77
 40.3
 41.3
 51.4
 42.6
BMI (mean, kg/m2)
 28.6 ± 5.1
 28.7 ± 5.0
 28.7 ± 4.6
 28.7 ± 4.5
 30.9 ± 5.6
 30.9 ± 5.7
 29.9 ± 5.0
 29.8 ± 4.8
     25–29.9 kg/m2 (%)
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 43.7
 42.6
     ≥30 kg/m2 (%)
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 42.4
 43.2
Waist-Hip-ratio







     Men
 n.a.
 n.a.
 n.a.
 n.a.
 0.96 ± 0.07
 0.96 ± 0.07
 0.99 ± 0.08
 0.98 ± 0.07
     Women
 n.a.
 n.a.
 n.a.
 n.a.
 0.86 ± 0.08
 0.87 ± 0.08
 0.90 ± 0.09
 0.90 ± 0.08
History of Hypertension (%)
 92.7*
 92.0*
 81*
 81*
 34.4
 43.5
 56.8
 59.8
Heart rate (bpm)
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 74.0 ± 9.4
 73.0 ± 9.8
Office systolic/diastolic BP (mmHg)
 154.5 ± 19.0/87.4 ± 10.9
 154.8 ± 19.0/87.6 ± 10.7
 164.1 ± 18.1/94.8 ± 10.4
 163.9 ± 18.0/94.5 ± 10.4
 136.1 ± 18.6/83.4 ± 10.8
 136.0 ± 18.1/83.4 ± 10.8
 147.4 ± 15.9/87.3 ± 9.3
 144.6 ± 15.3/86.5 ± 9.4
HbA1c (mean %)
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 5.6 ± 0.6
 5.6 ± 0.7
Risk factors







     Smoker (%)
 n.a.
 n.a.
 33
 32
 44.1
 45.0
 15.6
 13.6
     Dyslipidemia (%)
 n.a.
 n.a.
 n.a.
 n.a.
 35.6
 35.4
 56.4
 56.6
     Hyperuricemia (%)
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 21.7
 23.0
     MAU (%)
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 n.a.
 6.2
 5.4
     CHD (%)
 45.6
 46.0
 n.a.
 n.a.
 exclusion
 13.9
 14.2
     Stroke/TIA (%)
 19.8
 19.8
 n.a.
 n.a.
 exclusion
 exclusion
Drug therapy







     Aspirin or antiplatelet agents (%)
 n.a.
 n.a.
 19
 19
 14.3
 14.3
 27.7
 21.9
     Thiazide diuretics (%)
 35.9
 35.1
 n.a.
 n.a.
 9.5
 10.0
 0.4
 0
     Nonthiazide diuretics (%)

n.a.
 n.a.
 5.9
 5.6
 0
 0
     ACEi
 41.3
 41.4
 n.a.
 n.a.

0
 0.6
     ARBs (%)
 10.7
 10.6
 n.a.
 n.a.
 5.6
 5.3
 0.9
 1.2
     Betablockers (%)
 32.7
 33.7
 n.a.
 n.a.
 17.2
 17.5
 0.3
 0
     CCBs (%)
 41.7
 40.2
 n.a.
 n.a.
 12.8
 12.9
 18.6
 15.3
     Alphablockers (%)
 7.1
 6.5
 n.a.
 n.a.
 1.9
 2.2
 2.1
 2.0
     Statins (%)
 n.a.
 n.a.
 11**
 10**
 12.4
 13.5
 19.4
 17.4
     Fibrates (%)
 n.a.
 n.a.

2.1
 2.3
 0.1
 0

* previously treated for hypertension; n.a. = not available; BMI = body mass index; MAU = microalbuminuria; CHD = coronary heart disease; TIA = transitory ischemic attack; ACEi = ACE inhibitors; ARBs = Angiotensin receptor blockers; CCBs = calcium channel blockers

** statins and fibrates combined.

Zidek et al. Cardiovascular Diabetology 2008 7:22   doi:10.1186/1475-2840-7-22